The Asymmetry Advantage: Why Early Chiral Strategy Determines API Success

By: Kent Payne, Ph.D. (Managing Director), Alex Ziegelmeier, Ph.D. (Senior Research Scientist), Jason West, Ph.D. (Senior Research Scientist), and Hui-Yin ("Harry") Li, Ph.D. (Founder) — Wilmington PharmaTech

Chirality plays a pivotal role in pharmaceutical efficacy and safety, and chiral compounds now dominate today’s development pipelines. In this article, experts from Wilmington PharmaTech discuss the link between bioactivity and chirality, current market trends, and use real-world examples to explain the strategic advantages of asymmetric synthesis over chiral chromatographic purification.

While chromatography still has an important role, particularly in early development or when asymmetric routes are chemically impractical, the authors make a compelling case that relying on it too long can inflate cost of goods, extend timelines, and complicate regulatory submissions.

The Growing Dominance of Chiral Molecules

Chirality, the molecular property of handedness, has a profound impact on a drug’s biological behavior. Enantiomers, mirror-image isomers, can display dramatically different pharmacological profiles: one may deliver the desired therapeutic effect while its mirror image is inactive, counteractive, or even harmful. A well-known example is ethambutol, where the (S,S) enantiomer provides anti-tuberculosis activity, whereas the (R,R) form is roughly 500-fold less potent against the pathogen and is associated with optic toxicity.¹ These stark differences arise from stereospecific interactions with chiral biological targets such as enzymes and receptors, which typically recognize and bind only the correctly oriented enantiomer.

Chiral drugs now represent a substantial share of the pharmaceutical landscape. Analyses of FDA approvals from 2013–2022 show that roughly 60% of new small molecule drugs are single enantiomers, while achiral compounds account for 38–40% and racemates make up only a small fraction.² This marks a clear shift from earlier decades, when racemates were more common and regulatory expectations for enantiopure formulations were less stringent.

In the commercial market, chiral chemicals dominate pharmaceutical consumption, representing an estimated 70–72% of volume in 2023, driven largely by the demand for stereospecific APIs.³ This trend is mirrored in development pipelines where more than half of small molecule candidates contain at least one chiral center, as stereochemistry enables precise molecular recognition in complex therapeutic areas such as oncology and neurology. The global chiral chemicals market, valued at $77.4 billion in 2024, is projected to reach $125.8 billion by 2030,⁴ underscoring the industry’s deepening reliance on chiral compounds.

While the percentage of chiral drugs has stabilized at around 60% of approvals, the complexity, measured by the number of chiral centers per molecule, is increasing.⁵ Modern drugs, such as those targeting protein-protein interactions or multi-modal therapies, often incorporate 2–4 chiral centers, up from 1–2 in older molecules. This trend is evident in kinase inhibitors and biologics-inspired small molecules, where multi-chiral architectures enhance selectivity.

However, not all trends favor increased chirality; some pipelines show a slight decline in average chiral centers due to the rise of achiral modalities like PROTACs. Overall, the push for precision medicine drives more chiral complexity, with single enantiomers rising from 57% (2013–2017) to 59% (2018–2022) of approvals.⁶ This evolution reflects advancements in synthesis, enabling handling of intricate stereochemistry without prohibitive costs.

The Case for Early Purity Optimization

Chiral purity is essential for ensuring pharmaceutical safety and efficacy. Even small amounts of the undesired enantiomer can dilute potency, alter metabolic pathways, or introduce toxicities. A well-known example is esomeprazole, the single-enantiomer form of omeprazole, where improved stereochemical purity enhances acid-suppression performance.⁷ Regulatory agencies, including the FDA, typically expect chiral APIs to achieve enantiomeric excess values above 98%, underscoring the need for early optimization to avoid downstream clinical or regulatory setbacks.

For molecules containing multiple chiral centres, the challenge intensifies: each additional centre doubles the number of possible diastereomers, complicating purification and expanding impurity profiles. Rigorous optimization of stereochemical purity mitigates these risks, supporting consistent bioactivity, predictable pharmacokinetics, and a smoother regulatory review process.

Asymmetric Synthesis Versus Chiral Chromatographic Purification

Asymmetric synthesis and chiral chromatography represent two primary routes to enantiopure APIs, each with distinct advantages and drawbacks for clinical and commercial manufacturing.

Asymmetric synthesis uses stereoselective catalysis to generate the desired enantiomer directly, typically through chiral catalysts or auxiliaries. Its advantages include excellent scalability, reduced waste (since no 50% “wrong-enantiomer” fraction requires disposal) and compatibility with continuous processing. Together, these benefits streamline manufacturing, cut environmental burden, and minimize downstream purification steps. For commercial production, asymmetric synthesis can deliver strong cost-efficiency once the route is fully optimized. A well-known example is the biocatalytic process developed for sitagliptin, which replaced a rhodium-catalysed asymmetric hydrogenation and significantly reduced cost and environmental burden.⁸ However, the initial development is time-intensive, often requiring between six and 12 months, and may fail for sterically hindered substrates, requiring expert intervention.

Meanwhile, chiral chromatographic purification separates racemates post-synthesis using techniques like simulated moving bed (SMB) chromatography. Chiral chromatography provides rapid implementation for early-phase supplies which is ideal for low-volume clinical trials, and it works well for a wide range of molecular types. However, the process is inherently wasteful as there is a 50% yield loss of undesired enantiomer, and it adds extra production steps. Scalability is limited by high solvent consumption, significant equipment costs, and operational complexity. In commercial manufacturing, chromatographic processes can also introduce additional impurities and attract regulatory scrutiny around process robustness and reproducibility.

Cost and Long-Term Implications

Although there are high upfront costs, between $500k and $2M for route development, asymmetric synthesis yields between 20-50% lower cost of goods (COGs) at commercial-scale, compared to chromatography-inclusive routes.⁹ Notably, SMB chromatography can increase API production costs by 10-30%, due to solvent recovery, equipment amortization, and waste disposal. This equates to around $1M – $5M annually for a mid-scale campaign.

In contrast, once asymmetric routes have been validated, they eliminate the need for further purification process steps, reducing long-term manufacturing costs by between 15 and 40%. A tangible example of this includes Merck’s sitagliptin process which showed that biocatalytic asymmetric synthesis reduced COGs by 70% versus initial chromatographic methods.¹⁰ Some contract development and manufacturing organizations (CDMOs) have reported their asymmetric approaches have reduced client costs by 25-35% for scalable APIs, compared to chromoatography.¹¹

When considering commercial volumes (tons/year), the additional step in chromatography can increase costs between 20 and 50%, including validation and GMP compliance. The cost savings vary by molecule with simple chiral APIs that are ideal for synthesis can generate savings of more than 30%, where complex ones may necessitate hybrid approaches.

Early Investment in Asymmetric Synthesis: Pre-IND Evaluation

Chemists with extensive asymmetric experience create immense value by navigating complexity. Investing early in asymmetric experts, pre-IND, avoids downstream costs from chromatographic dependencies. Evaluating early, at discovery, can help teams identify viable routes and prevent scale-up bottlenecks. This can reduce long-term commercial manufacturing costs by 20-40% by eliminating purification steps. Notably, this has been seen in the case of sitagliptin which achieved reduction costs of multi-million dollars.¹²

Pre-IND asymmetric scouting can save $5M-$20M over a drug’s lifecycle by optimizing COGs and accelerating IND filing.¹³ For molecules with multiple stereocenters, conducting an early assessment helps manage development complexity and ensures alignment with regulatory expectations. Engaging the FDA through pre-IND discussions provides critical feedback at the right stage, reducing the risk of missteps later in the process. When this evaluation is delayed, teams often face the need to reformulate, adding significant time and cost — typically an additional 6–12 months and a 10–25% increase in overall expenses.

However, asymmetric synthesis is not feasible in around 20-30% of cases, for example, when intermediates are unstable or catalytic steps deliver unacceptably low yields. In these situations, developers must rely on chromatography instead. Conducting an early evaluation helps quantify this risk upfront, enabling teams to make informed decisions before committing significant time and resources.

Conclusion

As the pharmaceutical landscape continues to shift toward increasingly complex, stereochemically rich molecules, the importance of a well-defined chiral strategy has never been greater. While chiral chromatography remains a valuable tool, particularly in early development or when asymmetric routes are chemically unworkable, it is not a sustainable long-term solution for most APIs. The financial, operational, and regulatory burdens associated with chromatographic purification compound rapidly as programs advance, often creating avoidable delays and cost escalations.

In contrast, early investment in asymmetric synthesis offers a strategic advantage that extends far beyond route efficiency. By engaging asymmetric experts at the pre-IND stage, teams can identify viable stereoselective pathways, reduce reliance on high-waste purification methods, and build manufacturing processes that scale cleanly into commercial production.

References

1. Eishelbaum M, Testa B, Somogyi A. Stereochemical Aspects of Drug Action and Disposition. Berlin: Springer. 2003.
2. McVicker RU, O’Boyle NM. Chirality of new drug approvals (2013–2022): trends and perspectives. J Med Chem. 2024;67(4):2305-2320. doi:10.1021/acs.jmedchem.3c02239.
3. Grand View Research, Chiral Chemicals Market Size, Share & Trends Analysis Report (2024). Available at: Chiral Chemicals Market Size, Share | Industry Report, 2030. Accessed February 24, 2026.
4. IMARC Group, Chiral Chemicals Market Report (2024). Available at: Chiral Chemicals Market Size Report, Industry Analysis 2033. Accessed February 24, 2026.
5. McVicker RU, O’Boyle NM. Chirality of new drug approvals (2013–2022): trends and perspectives. J Med Chem. 2024;67(4):2305-2320. doi:10.1021/acs.jmedchem.3c02239.
6. McVicker RU, O’Boyle NM. Chirality of new drug approvals (2013–2022): trends and perspectives. J Med Chem. 2024;67(4):2305-2320. doi:10.1021/acs.jmedchem.3c02239.
7. Lin G-Q, Zhang J-G, Cheng J-F. Overview of chirality and chiral drugs. In: Chiral Drugs: Chemistry and Biological Action. Hoboken, New Jersey: Wiley; 2011.
8. Savile CK, Janey JM, Mundorff EC, et al. Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture. Science. 2010;329(5989):305-309. doi:10.1126/science.1188934.
9. Savile CK, Janey JM, Mundorff EC, et al. Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture. Science. 2010;329(5989):305-309. doi:10.1126/science.1188934.
10. Dapremont O. Chiral SMB: A Powerful Tool for Enantiomeric Separations. Phenomenex Blog. Published 2022. Available at: https://www.phenomenex.com/our-company/phenomenex-blog/industry-blogs/pharmaceutical/chiral-smb-olivier-dapremont. Accessed February 24, 2026.
11. Wilmington PharmaTech website facilities information page. Available at: https://wilmingtonpharmatech.com/facilities/. Accessed February 24, 2026.
12. Boyd Consultants, Pre-IND Meeting (2024).
13. Boyd Consultants, Pre-IND Meeting (2024).

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!